Lexeo Therapeutics (LXEO) Restructuring Costs (2024 - 2026)
Lexeo Therapeutics (LXEO) posted Restructuring Costs of $4.7 million for Q1 2026, down 49.47% sequentially from $9.3 million in Q4 2025, and down 62.52% YoY from $12.6 million in Q1 2025.
Lexeo Therapeutics (LXEO) Restructuring Costs (2024 - 2026) Analysis & Trends
Lexeo Therapeutics has reported Restructuring Costs for 3 years, with the latest figure at $4.7 million in Q1 2026.
- Quarterly Restructuring Costs fell 62.52% year-over-year to $4.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.1 million (down 10.78% YoY) and the FY2025 annual result came in at $37.0 million, up 48.06% from the prior year.
- Restructuring Costs fell to $4.7 million in Q1 2026 per LXEO's latest filing, from $9.3 million in the prior quarter.
- Over five years, Restructuring Costs peaked at $12.6 million in Q1 2025 and troughed at $2.9 million in Q3 2025.
- A 3-year average of $7.4 million and a median of $4.9 million in 2024 frame the typical range for Restructuring Costs.
- The sharpest annual moves came in 2025 and 2026: Restructuring Costs jumped 209.04% in 2025, then plunged 62.52% in 2026.
- Over 3 years, Restructuring Costs stood at $11.8 million in 2024, then decreased by 21.02% to $9.3 million in 2025, then sank by 49.47% to $4.7 million in 2026.
- According to Business Quant data, Restructuring Costs over the past three periods registered $4.7 million, $9.3 million, and $2.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Lexeo Therapeutics | 397.10 Mn | 397.10 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.95 Mn |
| Mar 31, 2026 | 4.71 Mn |
| Dec 31, 2025 | 9.32 Mn |
| Sep 30, 2025 | 2.87 Mn |
| Jun 30, 2025 | 12.24 Mn |
| Mar 31, 2025 | 12.57 Mn |
| Dec 31, 2024 | 11.80 Mn |
| Sep 30, 2024 | 4.34 Mn |
| Jun 30, 2024 | 3.96 Mn |
| Mar 31, 2024 | 4.89 Mn |